Received Feb 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Twinrix second dose on Sep 5th 2024 and received Engerix-B on Nov 5th 2024; Twinrix - Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 61-year-old female patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 15-SEP-2022). On 05-SEP-2024, the patient received the 2nd dose of Twinrix. On 05-NOV-2024, the patient received Engerix B. On 05-SEP-2024, an unknown time after receiving Twinrix and not applicable after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Twinrix - Late second dose). On 05-NOV-2024, the patient experienced inappropriate schedule of vaccine administered (Verbatim: Twinrix second dose on Sep 5th 2024 and received Engerix-B on Nov 5th 2024). The outcome of the drug dose administration interval too long and inappropriate schedule of vaccine administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-FEB-2025 The pharmacist reported that a patient received the first dose and second dose on 5th September 2024 of Twinrix series and that patient received a monovalent Hepatitis B vaccine (Engerix-B vaccine) on 5th November 2024, which led to inappropriate schedule of vaccine administered The reporter asked if they could complete the hepatitis A and B series with a Twinrix dose. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule.